---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-139962"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:16:37.956675+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences reports interim Phase 1b data for ABI-4334 with 2.9 log10 IU/mL mean HBV DNA reduction

## Summary
- ABI-4334 was well-tolerated with favorable safety profile; no serious adverse events or discontinuations in either cohort.
- In 150 mg dose cohort, mean HBV DNA declined 2.9 log10 IU/mL and mean HBV RNA declined 2.5 log10 U/mL over 28 days.
- Half-life supports once-daily oral dosing; Cmin multiples above EC50 for antiviral activity and cccDNA inhibition.
- Enrollment ongoing for 400 mg cohort, expected final cohort; data anticipated in first half of 2025.
- Gilead Sciences has opt-in rights to further develop and commercialize ABI-4334 after completion of Phase 1b study.

## SEC filing metadata
- accession: 0000950170-24-139962
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024139962/0000950170-24-139962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024139962/asmb-20241226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-139962
- JSON: https://secwatch.observer/filing/0000950170-24-139962.json
- Plain text: https://secwatch.observer/filing/0000950170-24-139962.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.